Mergers & Acquisitions ·
On September 9, 2026, Axogen, Inc. entered into a definitive merger agreement to acquire BioCircuit Technologies for…
AXGNAxogen, Inc.
On September 9, 2026, Axogen, Inc. entered into a definitive merger agreement to acquire BioCircuit Technologies for $200 million in cash, subject to customary adjustments. The transaction is expected to close in the fourth quarter of 2026 and will add NerveTape, the first FDA-approved device for sutureless peripheral nerve repair, to Axogen's portfolio. To finance the acquisition, Axogen priced a public offering of 4,910,000 shares at $42.50 per share on September 10, 2026, generating approximately $208.7 million in gross proceeds before underwriting discounts. The company intends to use substantially all net proceeds from the equity offering for the cash consideration and related fees. Axogen operates in the medical device industry, developing and commercializing surgical solutions for peripheral nerve regeneration and repair.